SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

OncoC4 Announces Cesalatamig Abstract Presentation at SITC

Data from a global Phase 1/2 study in PD-(L)1-resistant or refractory NSCLC are scheduled for presentation November 7.

Related stories